Joel Latham, Incannex Healthcare, on a Promising New Combination Therapy for Obstructive Sleep Apnea

Recently, Incannex Healthcare Inc. announced that patient dosing has commenced in their Phase 2/3 RePOSA clinical trial to assess the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (OSA). OSA is significantly undertreated in that there are no FDA approved prescribed medications and patient compliance to positive air way pressure (PAP) devices is low.
Earlier studies demonstrated that IHL-42X reduced the apnea hypopnea index (AHI), the standard measure of OSA, by an average of greater than 50% at the low dose and 25% of those patients had an 80% reduction.
DocWire News spoke with Joel Latham, President and CEO of Incannex, to find out more about the Company's proprietary fixed dose combination drug, and the positive impact it stands to have for patients with OSA.

[@warrenmartin2982]

Nice Interview, Great news for Shareholders the trials are progressing. Your Interviews are getting much better Joel well done. Can feel the excitement

[@mw9061]

cpaps make my apnea worse.